Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC5R | P33032 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | NOS1 | P29475 | 5/20 | 0.43 |
| ▸ | NOS3 | P29474 | 3/20 | 0.43 |
| ▸ | IFNAR1 | P17181 | 1/20 | 0.39 |
| ▸ | MC4R | P32245 | 2/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.37 |
| ▸ | ASH1L | Q9NR48 | 1/20 | 0.37 |
| ▸ | MC3R | P41968 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4846725 | 0.84 | MC5R (0.50) | MC5RMAPK1MC4RROCK1MC3R | |
| SCHEMBL4847363 | 0.83 | ROCK1 (0.49) | MC5RMAPK1ROCK1 | |
| SCHEMBL15345818 | 0.81 | CYP1A2 (0.50) | MC5RMAPK1ROCK1 | |
| SCHEMBL4850098 | 0.79 | MAPK1 (0.48) | MC5RMAPK1NOS1NOS3IFNAR1 | |
| SCHEMBL15345803 | 0.79 | LOXL2 (0.42) | MC5RMAPK1 | |
| SCHEMBL4846769 | 0.77 | CYP2D6 (0.42) | MC5RMAPK1NOS1MC4RSLC6A2 | |
| SCHEMBL15345477 | 0.76 | S1PR1 (0.47) | — | |
| SCHEMBL4840652 | 0.75 | MAPK1 (0.43) | MC5RMAPK1NOS1IFNAR1NOS2 | |
| SCHEMBL4844999 | 0.75 | HRH3 (0.41) | MC5RMC4RMC3R | |
| SCHEMBL15345427 | 0.75 | CSNK2A2 (0.47) | MC5RMAPK1ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368462-B1 | Melanin concentrating hormone antagonists | THE PROCTER & GAMBLE COMPANY (US) | 2008-05-06 | — | — | US | disclosed |
| US-20080058423-A1 | Melanin concentrating hormone antagonists | THE PROCTER & GAMBLE COMPANY | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058423-A1 | Melanin concentrating hormone antagonists | MCHR1, MCHR2, MC4R | MC5R 5/4885MAPK1 2262/4885NOS1 2945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.